Search

Your search keyword '"Ji, Linong"' showing total 176 results
Start Over Author "Ji, Linong" Publisher american diabetes association
176 results on '"Ji, Linong"'

2. Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled phase 2 trial

Author

Zhang, Bo, primary, Cheng, Zhifeng, primary, Chen, Ji, primary, Zhang, Xin, primary, Liu, Dexue, primary, Jiang, Hongwei, primary, Ma, Guoqing, primary, Wang, Xiaoyun, primary, Gan, Shenglian, primary, Sun, Juan, primary, Jin, Ping, primary, Yi, Jianjun, primary, Shi, Bimin, primary, Ma, Jianhua, primary, Ye, Shandong, primary, Wang, Guixia, primary, Ji, Linong, primary, Gu, Xuejiang, primary, Yu, Ting, primary, An, Pei, primary, Deng, Huan, primary, Li, Haoyu, primary, Li, Li, primary, Ma, Qingyang, primary, Qian, Lei, primary, and Yang, Wenying, primary

Published
2023
Full Text
View/download PDF

3. A Rare Variant in Metallothionein 1E Increases the Risk for Type 2 Diabetes in a Chinese Population

Author

Zou, Xiantong, primary, Hu, Mengdie, primary, Huang, Xiuting, primary, Zhou, Lingli, primary, Li, Meng, primary, CHEN, JING, primary, Ma, Liping, primary, Gao, Xueying, primary, Luo, Yingying, primary, Cai, Xiaoling, primary, Li, Yufeng, primary, Zhou, Xianghai, primary, Li, Na, primary, Shi, Yuanping, primary, Han, Xueyao, primary, and Ji, Linong, primary

Published
2023
Full Text
View/download PDF

4. Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.

Author

Zhang, Bo, Cheng, Zhifeng, Chen, Ji, Zhang, Xin, Liu, Dexue, Jiang, Hongwei, Ma, Guoqing, Wang, Xiaoyun, Gan, Shenglian, Sun, Juan, Jin, Ping, Yi, Jianjun, Shi, Bimin, Ma, Jianhua, Ye, Shandong, Wang, Guixia, Ji, Linong, Gu, Xuejiang, Yu, Ting, and An, Pei

Abstract

OBJECTIVE: We conducted a randomized, double-blind, placebo-controlled phase 2 trial to evaluate the efficacy and safety of mazdutide, a once-weekly glucagon-like peptide 1 and glucagon receptor dual agonist, in Chinese patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Adults with type 2 diabetes inadequately controlled with diet and exercise alone or with stable metformin (glycated hemoglobin A1c [HbA1c] 7.0–10.5% [53–91 mmol/mol]) were randomly assigned to receive 3 mg mazdutide (n = 51), 4.5 mg mazdutide (n = 49), 6 mg mazdutide (n = 49), 1.5 mg open-label dulaglutide (n = 50), or placebo (n = 51) subcutaneously for 20 weeks. The primary outcome was change in HbA1c from baseline to week 20. RESULTS: Mean changes in HbA1c from baseline to week 20 ranged from −1.41% to −1.67% with mazdutide (−1.35% with dulaglutide and 0.03% with placebo; all P < 0.0001 vs. placebo). Mean percent changes in body weight from baseline to week 20 were dose dependent and up to −7.1% with mazdutide (−2.7% with dulaglutide and −1.4% with placebo). At week 20, participants receiving mazdutide were more likely to achieve HbA1c targets of <7.0% (53 mmol/mol) and ≤6.5% (48 mmol/mol) and body weight loss from baseline of ≥5% and ≥10% compared with placebo-treated participants. The most common adverse events with mazdutide included diarrhea (36%), decreased appetite (29%), nausea (23%), vomiting (14%), and hypoglycemia (10% [8% with placebo]). CONCLUSIONS: In Chinese patients with type 2 diabetes, mazdutide dosed up to 6 mg was generally safe and demonstrated clinically meaningful HbA1c and body weight reductions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Rare Variant in Metallothionein 1E Increases the Risk of Type 2 Diabetes in a Chinese Population.

Author

Zou, Xiantong, Hu, Mengdie, Huang, Xiuting, Zhou, Lingli, Li, Meng, Chen, Jing, Ma, Liping, Gao, Xueying, Luo, Yingying, Cai, Xiaoling, Li, Yufeng, Zhou, Xianghai, Li, Na, Shi, Yuanping, Han, Xueyao, and Ji, Linong

Subjects
TYPE 2 diabetes, FATTY liver, CHINESE people, GLUCOSE metabolism, METALLOTHIONEIN, GENETIC variation
Abstract

OBJECTIVE: To uncover novel targets for the treatment of type 2 diabetes (T2D) by investigating rare variants with large effects in monogenic forms of the disease. RESEARCH DESIGN AND METHODS: We performed whole-exome sequencing in a family with diabetes. We validated the identified gene using Sanger sequencing in additional families and diabetes- and community-based cohorts. Wild-type and variant gene transgenic mouse models were used to study the gene function. RESULTS: Our analysis revealed a rare variant of the metallothionein 1E (MT1E) gene, p.C36Y, in a three-generation family with diabetes. This risk allele was associated with T2D or prediabetes in a community-based cohort. MT1E p.C36 carriers had higher HbA1c levels and greater BMI than those carrying the wild-type allele. Mice with forced expression of MT1E p.C36Y demonstrated increased weight gain, elevated postchallenge serum glucose and liver enzyme levels, and hepatic steatosis, similar to the phenotypes observed in human carriers of MT1E p.C36Y. In contrast, mice with forced expression of MT1E p.C36C displayed reduced weight and lower serum glucose and serum triglyceride levels. Forced expression of wild-type and variant MT1E demonstrated differential expression of genes related to lipid metabolism. CONCLUSIONS: Our results suggest that MT1E could be a promising target for drug development, because forced expression of MT1E p.C36C stabilized glucose metabolism and reduced body weight, whereas MT1E p.C36Y expression had the opposite effect. These findings highlight the importance of considering the impact of rare variants in the development of new T2D treatments. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

6. A comparison of daily glucose fluctuation among GCK-MODY and type 2 diabetes using continuous glucose monitoring technology

Author

Ren, Qian, primary, Zhang, Ping, primary, Pang, Wuyan, primary, Ma, Yumin, primary, Gong, Siqian, primary, Ba, Tianhao, primary, Liu, Wei, primary, Zhang, Fang, primary, Zhang, Xiuying, primary, Zhang, Rui, primary, Wang, Xiangqing, primary, Zhang, Xiaomei, primary, Yang, Wenjia, primary, Lv, Fang, primary, Gao, Leili, primary, Han, Xueyao, primary, and Ji, Linong, primary

Published
2023
Full Text
View/download PDF

7. A Comparison of Daily Glucose Fluctuation Between GCK-MODY and Type 2 Diabetes Using Continuous Glucose Monitoring Technology

Author

Ren, Qian, primary, Zhang, Ping, additional, Pang, Wuyan, additional, Ma, Yumin, additional, Gong, Siqian, additional, Ba, Tianhao, additional, Liu, Wei, additional, Zhang, Fang, additional, Zhang, Xiuying, additional, Zhang, Rui, additional, Wang, Xiangqing, additional, Zhang, Xiaomei, additional, Yang, Wenjia, additional, Lv, Fang, additional, Gao, Leili, additional, Han, Xueyao, additional, and Ji, Linong, additional

Published
2023
Full Text
View/download PDF

9. ADA/EASD Precision Medicine in Diabetes Initiative: An International Perspective and Future Vision for Precision Medicine in Diabetes

Author

Nolan, John J., primary, Kahkoska, Anna R., additional, Semnani-Azad, Zhila, additional, Hivert, Marie-France, additional, Ji, Linong, additional, Mohan, Viswanathan, additional, Eckel, Robert H., additional, Philipson, Louis H., additional, Rich, Stephen S., additional, Gruber, Chandra, additional, and Franks, Paul W., additional

Published
2022
Full Text
View/download PDF

18. Nonlaboratory-based risk assessment algorithm for undiagnosed type 2 diabetes developed on a nation-wide diabetes survey

Author

Zhou, Xianghai, Qiao, Qing, Ji, Linong, Ning, Feng, Yang, Wenying, Weng, Jianping, Shan, Zhongyan, Tian, Haoming, Ji, Qiuhe, Lin, Lixiang, Li, Qiang, Xiao, Jianzhong, Gao, Weiguo, Pang, Zengchang, and Sun, Jianping

Subjects
Health surveys -- Surveys, Dextrose -- Surveys, Risk assessment -- Surveys, Glucose -- Surveys, Glucose metabolism -- Surveys, Type 2 diabetes -- Diagnosis -- Surveys, Algorithms -- Surveys, Algorithm, Health
Abstract

OBJECTIVE--To develop a New Chinese Diabetes Risk Score for screening undiagnosed type 2 diabetes in China. RESEARCH DESIGN AND METHODS--Data from the China National Diabetes and Metabolic Disorders Study conducted [...]

Published
2013
Full Text
View/download PDF

19. A Low Frequency Genetic Variant in the Hepatic Glucokinase Gene is Associated with Type 2 Diabetes and Insulin Resistance in Chinese Population

Author

Admin, Ada, primary, Ma, Yumin, primary, Luo, Yingying, primary, Gong, Siqian, primary, Zhou, Xianghai, primary, Li, Yufeng, primary, Liu, Wei, primary, Zhang, Simin, primary, Cai, Xiaoling, primary, Ren, Qian, primary, Zhou, Lingli, primary, Zhang, Xiuying, primary, Wang, Yanai, primary, Huang, Xiuting, primary, Gao, Xueying, primary, Hu, Mengdie, primary, Han, Xueyao, primary, and Ji, Linong, primary

Published
2020
Full Text
View/download PDF

20. Low-Frequency Genetic Variant in the Hepatic Glucokinase Gene Is Associated With Type 2 Diabetes and Insulin Resistance in Chinese Population

Author

Ma, Yumin, primary, Luo, Yingying, additional, Gong, Siqian, additional, Zhou, Xianghai, additional, Li, Yufeng, additional, Liu, Wei, additional, Zhang, Simin, additional, Cai, Xiaoling, additional, Ren, Qian, additional, Zhou, Lingli, additional, Zhang, Xiuying, additional, Wang, Yanai, additional, Huang, Xiuting, additional, Gao, Xueying, additional, Hu, Mengdie, additional, Han, Xueyao, additional, and Ji, Linong, additional

Published
2020
Full Text
View/download PDF

21. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in china (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study

Author

Zhou, Zhiguang, Xiang, Yufei, Ji, Linong, Jia, Weiping, Ning, Guang, Huang, Gan, Yang, Lin, Lin, Jian, Liu, Zhenqi, Hagopian, William A., and Leslie, R. David

Subjects
Immunogenetics -- Research, Insulin resistance -- Genetic aspects -- Physiological aspects -- Health aspects, Prevalence studies (Epidemiology) -- Research, Type 2 diabetes -- Genetic aspects -- Physiological aspects -- Development and progression, Autoimmune diseases -- Physiological aspects -- Genetic aspects -- Development and progression, Health
Abstract

Adult non-insulin requiring diabetes includes latent autoimmune diabetes of adults (LADA), distinguished from type 2 diabetes by the presence of islet autoantibodies. LADA China determined the characteristics of Chinese LADA. This nationwide, multicenter, clinic-based cross-sectional study was conducted in 46 university-affiliated hospitals in 25 Chinese cities. All 4,880 ketosis-free diabetic patients (6 months, aged ≥ 30 years) had GAD antibody (GADA) and HLADQ genotype measured centrally with clinical data collected locally. GADA-positive subjects were classified as LADA. Of the patients, 5.9% were GADA positive with LADA. LADA showed a north-south gradient. Compared with GADA-negative type 2 diabetes, LADA patients were leaner, with lower fasting Coeptide and less metabolic syndrome. Patients with high GADA titers are phenotypicaUy different from those with low GADA titers, while only a higher HDL distinguished the latter from those with type 2 diabetes. HLA diabetes-susceptible haplotypes were more frequent in LADA, even in those with low-titer GADA. HLA diabetes-protective haplotypes were less frequent in LADA. Our study implicates universal immunogenetic effects, with some ethnic differences, in adult-onset autoimmune diabetes. Autoantibody positivity and titer could be important for LADA risk stratification and accurate therapeutic choice in clinical practice. Diabetes 62:543-550, 2013, Diabetes is prevalent worldwide, and the epidemic of diabetes is global, not least in China (1-4). Among children, autoimmune diabetes, known as type 1 diabetes, is the most prevalent form [...]

Published
2013
Full Text
View/download PDF

22. A genome-wide association study identifies GRK5 and RASGRP1 as Type 2 diabetes loci in Chinese Hans

Author

Li, Huaixing, Gan, Wei, Lu, Ling, Dong, Xiao, Han, Xueyao, Hu, Cheng, Yang, Zhen, Sun, Liang, Bao, Wei, Li, Pengtao, He, Meian, Sun, Liangdan, Wang, Yiqin, Zhu, Jingwen, Ning, Qianqian, Tang, Yong, Zhang, Rong, Wen, Jie, Wang, Di, Zhu, Xilin, Guo, Kunquan, Zuo, Xianbo, Guo, Xiaohui, Yang, Handong, Zhou, Xianghai, Zhang, Xuejun, Qi, Lu, Loos, Ruth J.F., Hu, Frank B., Wu, Tangchun, Liu, Ying, Liu, Liegang, Yang, Ze, Hu, Renming, Jia, Weiping, Ji, Linong, Li, Yixue, and Lin, Xu

Subjects
DNA replication -- Research, Single nucleotide polymorphisms -- Identification and classification, Type 2 diabetes -- Diagnosis -- Care and treatment -- Demographic aspects, Health
Abstract

Substantial progress has been made in identification of type 2 diabetes (T2D) risk loci in the past few years, but our understanding of the genetic basis of T2D in ethnically diverse populations remains limited. We performed a genome-wide association study and a replication study in Chinese Hans comprising 8,569 T2D case subjects and 8,923 control subjects in total, from which 10 single nucleotide polymorphisms were selected for further follow-up in a de novo replication sample of 3,410 T2D case and 3,412 control subjects and an in silico replication sample of 6,952 T2D case and 11,865 control subjects. Besides confirming seven established T2D loci (CDKAL1, CDKN2A/B, KCNQ1, CDC123, GLIS3, HNFIB, and DUSP9) at genome-wide significance, we identified two novel T2D loci, including G-protein-coupled receptor kinase 5 (GRK5) (rs10886471: P = 7.1 x [10.sup.-9 ) and RASGRP1 (rs7403531: P = 3.9 x [10.sup.-9]), of which the association signal at GRK5 seems to be specific to East Asians. In nondiabetic individuals, the T2D risk-increasing allele of RASGRPl-rs7403531 was also associated with higher [HbA1.sub.c] and lower homeostasis model assessment of β-cell function (P = 0.03 and 0.0209, respectively), whereas the T2D risk-increasing allele of GRK5-rs10886471 was also associated with higher fasting insulin (P = 0.0169) but not with fasting glucose. Our findings not only provide new insights into the pathophysiology of T2D, but may also shed light on the ethnic differences in T2D susceptibility., The prevalence of type 2 diabetes (T2D) has increased dramatically in China during the past few decades (1), and currently >92 million Chinese adults are estimated to have T2D (2). [...]

Published
2013
Full Text
View/download PDF

24. 1590-P: Effects of Second-Line Metformin Combination Therapies on Weight, HbA1c, and Risk of Hypoglycemia over 3 Years: The DISCOVER Study

Author

KHUNTI, KAMLESH, primary, CHARBONNEL, BERNARD, additional, COOPER, ANDREW, additional, GOMES, MARILIA B., additional, JI, LINONG, additional, LEIGH, PAUL, additional, NICOLUCCI, ANTONIO, additional, RATHMANN, WOLFGANG, additional, SHESTAKOVA, MARINA V., additional, SIDDIQUI, AFRAH, additional, TANG, FENGMING, additional, WATADA, HIROTAKA, additional, and CHEN, HUNGTA, additional

Published
2020
Full Text
View/download PDF

28. 961-P: Efficacy and Safety of Once-Weekly Semaglutide vs. Once-Daily Sitagliptin as Add-On to Metformin in Subjects with Type 2 Diabetes (SUSTAIN China MRCT): A 30-Week Double-Blind, Phase 3a, Randomised Trial

Author

JI, LINONG, primary, XIAOLIN, DONG, additional, ELIASCHEWITZ, FREDDY, additional, LI, YIMING, additional, LI, YUFENG, additional, LIM, SOO, additional, LIU, MING, additional, ZU, NING, additional, RASMUSSEN, SOEREN, additional, SKJOETH, TRINE V., additional, YUAN, GUOYUE, additional, and HUANG, YU-YAO, additional

Published
2020
Full Text
View/download PDF

31. 1598-P: HbA1c &lt;7.0% 6 Months after Initiation of Second-Line Therapy in Patients with Uncontrolled Type 2 Diabetes Is Associated with Good Glycemic Control at 3 Years: The DISCOVER Study

Author

BONNET, FABRICE, primary, CHEN, HUNGTA, additional, COOPER, ANDREW, additional, GOMES, MARILIA B., additional, JI, LINONG, additional, LEIGH, PAUL, additional, GUTIERREZ, LARISA RAMIREZ, additional, SHESTAKOVA, MARINA V., additional, SHIMOMURA, IICHIRO, additional, SIDDIQUI, AFRAH, additional, TANG, FENGMING, additional, VORA, JITEN, additional, WATADA, HIROTAKA, additional, and KHUNTI, KAMLESH, additional

Published
2020
Full Text
View/download PDF

34. 40-OR: Quality of Life in People with Type 2 Diabetes following Initiation of Second-Line Therapy: DISCOVER

Author

NICOLUCCI, ANTONIO, primary, CHEN, HUNGTA, additional, COOPER, ANDREW, additional, GOMES, MARILIA B., additional, JI, LINONG, additional, KHUNTI, KAMLESH, additional, KOSIBOROD, MIKHAIL N., additional, LEIGH, PAUL, additional, RAMIREZ, LARISA, additional, SHESTAKOVA, MARINA V., additional, SHIMOMURA, IICHIRO, additional, SIDDIQUI, AFRAH, additional, TANG, FENGMING, additional, VORA, JITEN, additional, WATADA, HIROTAKA, additional, and ARNOLD, SUZANNE V., additional

Published
2020
Full Text
View/download PDF

40. 18-OR: Efficacy and Safety of Chiglitazar vs. Sitagliptin in Patients with Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Noninferiority Phase 3 Trial (CMAS)

Author

JIA, WEIPING, primary, MA, JIANHUA, additional, MIAO, HENG, additional, WANG, CHANGJIANG, additional, WANG, XIAOYUE, additional, LI, QUANMIN, additional, LU, WEIPING, additional, YANG, JIALIN, additional, ZHANG, LIHUI, additional, YANG, JINKUI, additional, WANG, GUIXIA, additional, ZHANG, XIUZHENG, additional, ZHANG, MIN, additional, SUN, LI, additional, YU, XUEFENG, additional, DU, JIANLING, additional, SHI, BINGYIN, additional, XIAO, CHANGQING, additional, ZHU, DALONG, additional, LIU, HONG, additional, ZHONG, LIYONG, additional, XU, CHUN, additional, XU, QI, additional, LIANG, GANXIONG, additional, ZHANG, YING, additional, LI, GUANGWEI, additional, GU, MINGYU, additional, LIU, JUN, additional, NING, ZHIQIANG, additional, and JI, LINONG, additional

Published
2019
Full Text
View/download PDF

42. 1080-P: A Prospective, Multicenter, Randomized, Open-Label, Parallel-Group Clinical Trial Comparing Patient Satisfaction and Compliance with a Needle-Free Insulin Injector vs. Conventional Insulin Pen Injections in Chinese Patients with Type 2 Diabetes Mellitus

Author

WANG, YANGANG, primary, JI, LINONG, additional, GUO, LIXIN, additional, RAN, XINGWU, additional, CHEN, LIMING, additional, MA, ZHONGSHU, additional, SUN, ZILIN, additional, SHAN, ZHONGYAN, additional, XU, XIANGJIN, additional, and WANG, GUIXIA, additional

Published
2019
Full Text
View/download PDF

43. 17-OR: Efficacy and Safety of Chiglitazar, a Novel PPARα/γ/d Pan-Agonist, in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Superiority Trial (CMAP)

Author

JI, LINONG, primary, SONG, WEIHONG, additional, FANG, HUI, additional, LI, WEI, additional, GENG, JIANLIN, additional, XU, YAN CHENG, additional, WANG, YANGANG, additional, GUO, LIAN, additional, CAI, HANQING, additional, YANG, TAO, additional, LI, HONG-MEI, additional, YANG, GANGYI, additional, LI, QIFU, additional, LIU, KUANZHI, additional, LI, SHUYING, additional, LIU, YANJUN, additional, SHI, FUYAN, additional, LI, XIN SHENG, additional, GAO, XIN, additional, JI, QIUHE, additional, TIAN, HAOMING, additional, SU, QING, additional, ZHOU, ZHIGUANG, additional, WANG, WENBO, additional, ZHOU, ZUNHAI, additional, LI, XUEJUN, additional, NING, ZHIQIANG, additional, LU, XIANPING, additional, and JIA, WEIPING, additional

Published
2019
Full Text
View/download PDF

47. Low-Frequency Genetic Variant in the Hepatic Glucokinase Gene Is Associated With Type 2 Diabetes and Insulin Resistance in Chinese Population.

Author

Ma, Yumin, Luo, Yingying, Gong, Siqian, Zhou, Xianghai, Li, Yufeng, Liu, Wei, Zhang, Simin, Cai, Xiaoling, Ren, Qian, Zhou, Lingli, Zhang, Xiuying, Wang, Yanai, Huang, Xiuting, Gao, Xueying, Hu, Mengdie, Han, Xueyao, and Ji, Linong

Subjects
TYPE 2 diabetes, CHINESE people, GLUCOKINASE, INSULIN resistance, INSULIN sensitivity, INSULIN, RESEARCH, GENETICS, LIVER, RESEARCH methodology, BLOOD sugar, EVALUATION research, COMPARATIVE studies, TRANSFERASES, GENES, GLUCOSE tolerance tests, PREDIABETIC state, PHYSIOLOGY
Abstract

Glucokinase (GCK) regulates insulin secretion and hepatic glucose metabolism, and its inactivating variants could cause diabetes. We aimed to evaluate the association of a low-frequency variant of GCK (rs13306393) with type 2 diabetes (T2D), prediabetes, or both (impaired glucose regulation [IGR]) in a Chinese population. An association study was first conducted in a random cluster sampling population (sample 1: 537 T2D, 768 prediabetes, and 1,912 control), and then another independent population (sample 2: 3,896 T2D, 2,301 prediabetes, and 868 control) was used to confirm the findings in sample 1. The A allele of rs13306393 was associated with T2D (odds ratio 3.08 [95% CI 1.77-5.36], P = 0.00007) in sample 1; rs13306393 was also associated with prediabetes (1.67 [1.05-2.65], P = 0.03) in sample 2. In a pooled analysis of the two samples, the A allele increased the risk of T2D (1.57 [1.15-2.15], P = 0.005), prediabetes (1.83 [1.33-2.54], P = 0.0003) or IGR (1.68 [1.26-2.25], P = 0.0004), insulin resistance estimated by HOMA (β = 0.043, P = 0.001), HbA1c (β = 0.029, P = 0.029), and urinary albumin excretion (β = 0.033, P = 0.025), irrespective of age, sex, and BMI. Thus, the Chinese-specific low-frequency variant increased the risk of T2D through reducing insulin sensitivity rather than islet β-cell function, which should be considered in the clinical use of GCK activators in the future. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

48. New susceptibility locus for NIDDM is localized to human chromosome 20q

Author

Ji, Linong, Malecki, Maciek, Warram, James H., Yang, Yadong, Rich, Stephen S., and Krolewski, Andrzej S.

Subjects
Type 2 diabetes -- Genetic aspects, Health, Genetic aspects
Abstract

To test the hypothesis that a gene (or genes) in the 'MODY1 region' of the long arm of chromosome 20 contributes to the development of NIDDM, we conducted linkage studies [...]

Published
1997

49. Trinucleotide repeats at the rad locus: allele distributions in NIDDM and mapping to a 3-cM region on chromosome 16q

Author

Doria, Alessandro, Caldwell, James S., Ji, Linong, Reynet, Christine, Rich, Stephen S., Weremowicz, Stanislawa, Morton, Cynthia C., Warram, James H., Kahn, C. Ronald, and Krolewski, Andrzej S.

Subjects
Type 2 diabetes -- Genetic aspects, Chromosome mapping -- Usage -- Genetic aspects, Health, Usage, Genetic aspects
Abstract

A 10-allele polymorphism was identified in rad (ras associated with diabetes), a gene that is overexpressed in non-insulin-dependent diabetes mellitus (NIDDM) muscle. The polymorphism, designated RAD1, consists of a variable number of trinucleotide repeats (GTT and ATT) located in the poly(A) region of an intronic Alu sequence. Based on the number of GTT and ATT repetitions, the alleles can be grouped into four classes (I-IV). RAD1 allele frequencies were determined in 210 NIDDM patients and 133 nondiabetic control subjects, all Caucasians. One allele (number 8, class III) accounted for >80% of the chromosomes in both groups. However, an excess of minor alleles, all belonging to class I, II, or IV, was observed among NIDDM chromosomes (P < 0.025), suggesting a possible association between RAD1 and NIDDM predisposition. To promote further studies to test the hypothesis that genetic variability at the rad locus contributes to NIDDM, we mapped rad on the human genome. Using the fluorescence in situ chromosomal hybridization technique, rad was unequivocally assigned to chromosomal band 16q22. In families that were informative for RAD1, the rad locus was mapped within a 3-cM region defined by the markers D16S265, D16S186, and D16S397 (logarithm of odds scores = 10.08, 10.9, and 10.84 at recombination fractions of 0.024, 0.001, and 0.03, respectively). The high degree of heterozygosity of these markers will allow large-scale family studies to be performed to test the presence of linkage between rad and NIDDM. Diabetes 44:243-247, 1995, Despite remarkable advances in molecular genetics, the genetic determinants of non-insulin-dependent diabetes mellitus (NIDDM) remain largely unknown. Mutations in genes for insulin, the insulin receptor, and glucokinase, as well as [...]

Published
1995

50. Twelve-Month Changes in HbA1c, Fasting Plasma Glucose, and Weight among Patients with Type 2 Diabetes in 37 Countries—DISCOVER

Author

CHARBONNEL, BERNARD, primary, BONNET, FABRICE, additional, CHEN, HUNGTA, additional, CID-RUZAFA, JAVIER, additional, FENICI, PETER, additional, GOMES, MARILIA B., additional, HAMMAR, NIKLAS, additional, JI, LINONG, additional, KENNEDY, KEVIN, additional, KOSIBOROD, MIKHAIL, additional, POCOCK, STUART, additional, RATHMANN, WOLFGANG, additional, SHESTAKOVA, MARINA V., additional, SHIMOMURA, IICHIRO, additional, SURMONT, FILIP, additional, and KHUNTI, KAMLESH, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results